Evofem Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except par value and share data)
| As of | ||
|---|---|---|
| September 30, 2024 | December 31, 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents · $ · - · $ · - | ||
| Restricted cash | 722 | 580 |
| Trade accounts receivable, net | 5,393 | 5,738 |
| Inventories | 1,463 | 1,697 |
| Prepaid and other current assets | 999 | 1,195 |
| Total current assets | 8,577 | 9,210 |
| Property and equipment, net | 1,181 | 1,203 |
| Operating lease right-of-use assets | 127 | 106 |
| Intangible asset, net (Note 7) | 14,021 | - |
| Other noncurrent assets | 36 | 35 |
| Total assets | $23,942 | $10,554 |
| Liabilities, convertible and redeemable preferred stock and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $16,864 | $17,020 |
| Notes - carried at fair value (Note 4) | 14,183 | 14,731 |
| Convertible notes - Adjuvant (Note 4) | 30,202 | 28,537 |
| Short term debt | 268 | - |
| Accrued expenses | 5,124 | 4,227 |
| Accrued compensation | 3,222 | 2,609 |
| Operating lease liabilities - current | 116 | 97 |
| Derivative liabilities | 162 | 1,926 |
| Contingent liabilities – current (Note 7) | 808 | - |
| Other current liabilities | 4,652 | 3,316 |
| Other current liabilities - related party | 685 | - |
| Total current liabilities | 76,286 | 72,463 |
| Operating lease liabilities- noncurrent | 10 | 8 |
| Contingent liabilities – noncurrent (Note 7) | 13,775 | - |
| Total liabilities | 90,071 | 72,471 |
| Commitments and contingencies (Note 7) | - | - |
| Convertible and redeemable preferred stock, $0.0001 par value, senior to common stock | ||
| Series E-1 and F-1 convertible preferred stock, 2,300 and 95,000 shares authorized; 2,017 and 1,874 shares of E-1 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; 23,540 and 22,280 shares of F-1 issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 4,759 | 4,593 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 | - | - |
| Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 100,328,686 and 20,007,799 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 10 | 2 |
| Additional paid-in capital | 825,430 | 823,036 |
| Accumulated other comprehensive loss | (1,707) | (849) |
| Accumulated deficit | (894,621) | (888,699) |
| Total stockholders’ deficit | (70,888) | (66,510) |
| Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit | $23,942 | $10,554 |
See accompanying notes to the condensed consolidated financial statements (unaudited).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.